Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai’s H1 Operating Profit Spikes on Lenvima Growth, Divestment Gain
November 8, 2023
- Air Pollutant Might Be to Blame for NDMA Formation in Metformin: Towa Paper
November 7, 2023
- Izervay Slows Geographic Atrophy Lesion Growth through 2 Years: Astellas
November 7, 2023
- Nobelpharma Seeks Provisional Disposition against Sawai’s Nobelzin Copy
November 7, 2023
- Chugai Offloading Xeloda to Cheplapharm after German Firm Plants Flag in Japan
November 7, 2023
- BMS Seeks to Block Sawai’s Sprycel Generic over CML Use
November 7, 2023
- Xocova Claims 1st Trophy in August GP Promotion, Dayvigo Makes Comeback in HP List
November 6, 2023
- Kazunari Tsunaba Steps Down as CEO of Aculys Pharma
November 6, 2023
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Shionogi, Apnimed to Launch Joint Venture to Develop Sleep Apnea Drugs
November 2, 2023
- Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
November 2, 2023
- Mitsubishi Tanabe’s April-September Sales Up 8% on Radicava
November 2, 2023
- Kyowa Kirin Drops Acoalan’s Preeclampsia Program after PIII Miss
November 2, 2023
- Otsuka Ups 2023 Full-Year Sales Forecast on Bullish Global Brands
November 2, 2023
- Shionogi, Mochida Form Sales Tie-Up for Daridorexant in Japan
November 2, 2023
- Daiichi Sankyo to Merge 2 Subsidiaries to Enhance ADC Production
November 1, 2023
- Otsuka Files Rexulti for Alzheimer’s Associated Agitation in Japan
November 1, 2023
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Otsuka Calls Off PIII Bipolar Trial for SEP-4199 on Stalled Recruitment
November 1, 2023
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…